Tsu-Yi Chao

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 953 citations

Medicine, Oncology, Pharmacology +10

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su et al. · Hepatology · 2008 · 306 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

The Uniform Approach to Breast Fine Needle Aspiration Biopsy

Marluce Bibbo, Andrea Abati, Alex Ferenczy et al. · Acta Cytologica · 1996 · 145 citations

Medicine, Oncology, Pathology +9

Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling

Chien‐Tai Hong, Kai‐Yun Chen, Weu Wang et al. · Cells · 2020 · 131 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17